Previous 10 | Next 10 |
Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort - - - Median progression free survival (PFS) of 12.5 months compared with 5.4 months in a historical coh...
Penny Stocks To Watch As Earnings Season Rolls On It’s earnings season but that hasn’t distracted the market from things like the coronavirus or the Fed meeting. But given this, the higher volatility market has brought more attention to penny stocks . When investors look for big...
Are Any of These Penny Stocks On Your Watch List This Week? Finding the best penny stocks to buy , let alone the best penny stocks to watch can be a difficult thing to do. It’s not a matter of finding the companies either. But rather researching the finer details of what could drive ...
Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP ) +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...
January 28, 2020 Palm Beach, FL – January 28, 2020 – Brain and other nervous system cancers are the 10th leading cause of death for men and women. The global G lioblastoma multiforme (GBM) drugs market to reach nearly $1.4 billion by 2025, expanding at a CAGR o...
These Penny Stocks Are Expecting To Release New Data This Week If there’s one thing investing in penny stocks has taught us, it’s to look for potential catalysts anywhere you can find them. Sometimes it’s easier said than done, to be honest. But proper research is a skil...
Are These Companies On Your Penny Stocks Watch List Right Now? It is a well-known fact that investors are always on the lookout for promising penny stocks. The simple reason behind that is the fact that these stocks can generate enormous returns. Over the years, many investors have made money ...
BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new efficacy and safety data from it...
Amyris (NASDAQ: AMRS ) initiated with Outperform rating and $8 (147% upside) price target at Oppenheimer. Shares up 8% premarket. More news on: Amyris, Inc., Bausch Health Companies Inc., Globus Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Aimed at delivering key milestones next year, Miragen (NASDAQ: MGEN ) announces major changes in its strategy. Key points: More news on: Miragen Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...